---
title: "Tirabrutinib in Primary central nervous system lymphoma: Clinical evidence"
description: "Formulary evidence on Tirabrutinib in Primary central nervous system lymphoma: Clinical evidence. Covers PROSPECT, ONO-4059-02, IGNITE, ReSTART (JCOG2314), Japanese post-marketing surveillance, ROSETTA, and 15 further headings. 161 evidence topics quoted from 32 sources."
canonical: "https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tirabrutinib in Primary central nervous system lymphoma: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 PROSPECT

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Monotherapy and first-line combination objectives

> “This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)”

Source: [National Cancer Institute NCI-2021-14196](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-14196)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Part A data cutoff

> “November 1, 2024”

Source: [Nayak et al. (2025a)](https://doi.org/10.1002/hon.70093_88)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Part A trial design

> “open-label phase II study”

Source: [Nayak et al. (2025a)](https://doi.org/10.1002/hon.70093_88)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Part A key eligibility criteria

> “Patients aged ≥ 18 years on the day of consenting to the study”
> “Pathologic diagnosis of PCNSL”
> “Relapse or refractory PCNSL with at least one prior high dose methotrexate (HD-MTX) based therapy for PCNSL”
> “Eastern Cooperative Oncology Group performance score (ECOG PS) of 0, 1 or 2”

Source: [National Cancer Institute NCI-2021-14196](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-14196)

<a id="topic-3.1.1.4-2"></a>

###### Part B newly diagnosed population

> “Adults at least 18 years of age who have been newly diagnosed with PCNSL.”

Source: [PROSPECT study website](https://theprospectstudy.com/)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Part A monotherapy

> “oral tirabrutinib 480 mg”
> “once daily”

Source: [Nayak et al. (2025a)](https://doi.org/10.1002/hon.70093_88)

<a id="topic-3.1.1.5-2"></a>

###### Part B chemotherapy combinations

> “MTR: Methotrexate/ temozolomide/ rituximab”
> “R-MPV: Rituximab/ methotrexate/ procarbazine/ vincristine”

Source: [PROSPECT study website](https://theprospectstudy.com/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Overall Response Rate as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Validation as a surrogate for survival

No evidence found.

Additional sources: [Nayak et al. (2025a)](https://doi.org/10.1002/hon.70093_88)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Part A enrollment

> “Forty-eight patients were enrolled.”

Source: [Nayak et al. (2025a)](https://doi.org/10.1002/hon.70093_88)

<a id="topic-3.1.1.7.1-2"></a>

###### Part B planned enrollment

> “About 70 participants will be enrolled to Part B in the PROSPECT study in the United states.”

Source: [PROSPECT study website](https://theprospectstudy.com/)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Part A ongoing treatment at data cutoff

> “At data cutoff, 13 patients (27%) remained on tirabrutinib treatment.”

Source: [ONO Pharma and Deciphera Pharmaceuticals (2025)](https://www.deciphera.com/news/ono-pharma-presents-positive-results-pivotal-trial-us-patients-relapsed-or-refractory-pcnsl-0)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Part A age

> “Median age was 65.5 y (range, 34-87).”

Source: [Nayak et al. (2025a)](https://doi.org/10.1002/hon.70093_88)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Part A response and time-to-event outcomes

> “With an ORR of 66.7%, CR/CRu rate of 43.8%, median DOR of 9.3 mo”
> “median PFS was 6.0 mo”

Source: [Nayak et al. (2025a)](https://doi.org/10.1002/hon.70093_88)

<a id="topic-3.1.1.8.3-2"></a>

###### Part B efficacy results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Part A treatment-emergent adverse events

> “Incidence of grade ≥3 treatment-emergent adverse events (TEAEs) was 56.3%.”
> “Two patients died of TEAEs, which were considered unrelated to study treatment.”

Source: [ONO Pharma and Deciphera Pharmaceuticals (2025)](https://www.deciphera.com/news/ono-pharma-presents-positive-results-pivotal-trial-us-patients-relapsed-or-refractory-pcnsl-0)

<a id="topic-3.1.1.8.5-2"></a>

###### Part A treatment-related adverse events

> “grade ≥3 TRAEs were experienced by 27%, most frequently neutrophil count decreased (8%) and maculo-papular rash (6%).”

Source: [Nayak et al. (2025b)](https://academic.oup.com/neuro-oncology/article/27/Supplement_5/v135/8318896)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

Part A enrolled 48 participants in an open-label phase II study. The reported response and survival estimates do not establish comparative benefit against another treatment. Enrollment required an ECOG performance score of 0, 1, or 2, limiting direct applicability to participants with worse performance status. Part A monotherapy results should not be extrapolated to Part B chemotherapy combinations.

Source: [Nayak et al. (2025a)](https://doi.org/10.1002/hon.70093_88); [National Cancer Institute NCI-2021-14196](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-14196); [PROSPECT study website](https://theprospectstudy.com/)

<a id="heading-3.1.2"></a>

#### 3.1.2 ONO-4059-02

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Long-term follow-up assessments

> “The secondary endpoints included investigator-assessed ORR, best overall response (BOR), duration of response (DOR), time to response, progression-free survival (PFS), and overall survival (OS).”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study sites and initiation

> “This was an exploratory analysis of an ongoing multicenter, open-label, uncontrolled phase I/II study conducted across 10 sites in Japan from October 2017.”

Source: [Arakawa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10517093/)

<a id="topic-3.1.2.2-2"></a>

###### Enrollment period

> “Between October 19, 2017, and June 13, 2019, 44 patients were enrolled: 33 and 9 had relapsed and refractory, respectively.”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Trial design

> “open-label, uncontrolled phase I/II study”

Source: [Arakawa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10517093/)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Eligibility and exclusions

> “Eligible patients were those with age ≥ 20 years; histologically diagnosed, previously treated relapsed/refractory PCNSL; a brain lesion with the major axis > 1.0 cm; a KPS score ≥ 70; and expected lifetime ≥ 3 months.”
> “Patients without B-cell type PCNSL and those with systemic lesions were excluded.”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Dose groups and treatment duration

> “In the ONO-4059-02 open-label, single-arm, phase 1/2 study (Japanese Registry of Clinical Trials identifier, jRCT2080223590), patients with relapsed/refractory PCNSL were administered oral tirabrutinib q.d. at a dose of 320 or 480 mg, or 480 mg under fasted condition.”
> “The treatment was continued over 28-day cycles until disease progression or unacceptable toxicities were observed.”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using IPCG Overall Response Rate as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Central response assessment

> “The primary endpoint was the overall response rate (ORR) assessed by a central independent review committee, according to the International PCNSL Collaborative Group guidelines”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="topic-3.1.2.6.1-2"></a>

###### Histological support from one trial participant

> “An autopsy confirmed no viable tumor cells in the entire brain, including the left cerebellum lesion, confirming complete obliteration of tumor cells by tirabrutinib.”

Source: [Okita et al. (2021)](https://link.springer.com/article/10.1186/s40164-021-00222-5)

<a id="topic-3.1.2.6.1-3"></a>

###### Validation as a surrogate for survival

No evidence found.

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned phase I and phase II enrollment

> “The planned number of patients for enrollment was 3 or 6 for each cohort (320 or 480 mg) in the phase 1 part and 15 in the phase 2 part.”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="topic-3.1.2.7.1-2"></a>

###### Actual enrollment

> “Forty-four patients were enrolled”

Source: [Narita et al. (2021)](https://academic.oup.com/neuro-oncology/article/23/1/122/5862521)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Safety and efficacy analysis sets

> “Safety was assessed in all patients who received ≥ 1 dose of study treatment.”
> “Within the safety set, those who had ≥ 1 measurable lesion before the start of treatment and had ≥ 1 centrally assessed BOR were assessed for the efficacy endpoints.”
> “Two-sided 95% confidence intervals (CIs) were calculated using the Clopper-Pearson method.”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="topic-3.1.2.7.2-2"></a>

###### Quality-of-life analysis population and statistical testing

> “The analysis population consisted of 44 patients from the full analysis set.”
> “The mixed model for repeated measures was used to evaluate the systematic transition of scale change, in which time points (cycles) and participants were used as a repeated fixed factor and a random factor, respectively.”
> “The scale changes from baseline over time were evaluated with adjusted P-value using Dunnett’s multiple comparison method and the statistical significance level was set to be .05.”

Source: [Arakawa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10517093/)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Treatment continuation and subsequent therapy

> “The number of patients who continued treatment with tirabrutinib for 6 months, 1, 2, or 3 years was 20, 15, 8, and 6, respectively.”
> “A total of 42 patients (95.5%) terminated treatment (including those who completed study treatment) and 2 patients received ongoing treatment with marketed tirabrutinib.”
> “Of 42 patients who terminated tirabrutinib treatment, 32 (72.7%) started to receive subsequent treatment, including 28 (63.6%) who had disease progression under the treatment with tirabrutinib.”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Age, performance status, and prior treatment

> “In the overall population, the median age was 60.0 years (range, 29–86) and the median for KPS scores was 80.0 (range, 70–100).”
> “The median number of previous lines of treatment was 2.0 (range, 1–14).”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Initial response assessment

> “Independent review committee assessed overall response rate (ORR) at 64%”

Source: [Narita et al. (2021)](https://academic.oup.com/neuro-oncology/article/23/1/122/5862521)

<a id="topic-3.1.2.8.3-2"></a>

###### Three-year follow-up

> “The median DOR was 9.2 (95% CI: 1.7–17.2) months in the overall population”
> “The 3-year OS rate was 56.7% in the overall population”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="topic-3.1.2.8.3-3"></a>

###### Long-term progression-free survival

> “The 3-year PFS rate was 13.9% in the overall population”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="topic-3.1.2.8.3-4"></a>

###### Radiological response in the autopsy case

> “The left cerebellum lesions on magnetic resonance imaging disappeared one month after tirabrutinib treatment.”

Source: [Okita et al. (2021)](https://link.springer.com/article/10.1186/s40164-021-00222-5)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### Performance status and quality-of-life findings

> “Tirabrutinib generally maintains KPS and QoL scores with some improvements in specific QoL items in patients with r/r PCNSL.”

Source: [Arakawa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10517093/)

<a id="topic-3.1.2.8.4-2"></a>

###### Reported quality-of-life trajectory

> “The global health status/QoL in the QLQ-C30 showed significant improvements from baseline through cycles 3–17 and remained relatively constant thereafter until cycle 23.”

Source: [Arakawa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10517093/)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Initial fatal adverse events

> “One patient had grade 5 AEs (pneumocystis jirovecii pneumonia and ILD)”

Source: [Narita et al. (2021)](https://academic.oup.com/neuro-oncology/article/23/1/122/5862521)

<a id="topic-3.1.2.8.5-2"></a>

###### Long-term adverse-event incidence

> “Any-grade AEs occurred in 38 patients (86.4%) and grade ≥ 3 AEs occurred in 23 patients (52.3%).”
> “The most frequent any-grade AEs were rash (36.4%), neutropenia (27.3%), leukopenia (25.0%), and lymphopenia (18.2%).”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The study was uncontrolled and enrolled 44 participants with KPS scores of at least 70. Results therefore do not establish comparative efficacy or directly characterize participants with lower performance status. Subsequent therapy was reported for 32 participants, limiting attribution of long-term overall survival to tirabrutinib alone. Quality-of-life analyses were exploratory, were not planned when the protocol was fixed, and lacked follow-up after tirabrutinib discontinuation. The autopsy publication describes a participant from this trial, not an independent efficacy cohort.

Source: [Arakawa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10517093/); [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/); [Okita et al. (2021)](https://link.springer.com/article/10.1186/s40164-021-00222-5)

<a id="topic-3.1.2.9-2"></a>

###### Exploratory quality-of-life analysis and missing follow-up

> “This was an exploratory analysis because the statistical analysis was not planned when the protocol was fixed.”
> “Follow-up data on KPS and QoL after tirabrutinib discontinuation were not obtained, preventing an examination of changes compared to the continuation group.”

Source: [Arakawa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10517093/)

<a id="heading-3.1.3"></a>

#### 3.1.3 IGNITE

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Randomized comparison

> “tirabrutinib vs rituximab and temozolomide combination therapy in R/R PCNSL”

Source: [Nayak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13374761/)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study initiation

> “study started June 12, 2026”

Source: [University of California, Irvine](https://clinicaltrials.icts.uci.edu/trial/NCT07104032)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Phase III design

> “ongoing, phase III, multiregional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide combination therapy in R/R PCNSL.”

Source: [Nayak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13374761/)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Age and functional eligibility

> “ages 18 years and up”
> “Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2”

Source: [University of California, Irvine](https://clinicaltrials.icts.uci.edu/trial/NCT07104032)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Treatment comparison

> “tirabrutinib vs rituximab and temozolomide combination therapy”

Source: [Nayak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13374761/)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using IPCG Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary and secondary endpoints

> “The primary endpoint is progression-free survival”
> “The primary endpoint is progression-free survival based on blinded independent review committee (BIRC) per International PCNSL Collaborative Group (IPCG) criteria.”
> “Key secondary endpoints are overall response rate based on BIRC per IPCG criteria and overall survival.”

Source: [Nayak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13374761/)

<a id="topic-3.1.3.6.1-2"></a>

###### Validation as a surrogate for survival

No evidence found.

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The retained publication describes an ongoing, open-label randomized trial with blinded independent review of progression-free survival. It does not provide comparative efficacy or safety results. Progression-free survival is the primary endpoint; overall survival is a secondary endpoint.

Source: [Nayak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13374761/)

<a id="heading-3.1.4"></a>

#### 3.1.4 ReSTART (JCOG2314)

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Non-inferiority and functional objectives

> “We designed a multicenter, randomized phase II/III trial (JCOG2314) to assess the non-inferiority of tirabrutinib to WBRT in overall survival and its potential to reduce functional deterioration and cognitive impairment.”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Trial activation

> “activated in January 2026”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="topic-3.1.4.2-2"></a>

###### Participating centers and accrual period

> “A total of 94 patients from 49 institutions will be enrolled over 4 years.”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Randomized treatment assignment

> “Eligible patients with refractory primary central nervous system lymphoma (PCNSL) are randomly assigned to receive either whole-brain radiotherapy (WBRT) or tirabrutinib.”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="topic-3.1.4.3-2"></a>

###### Trial setting

> “This is a multicenter (49 specialized centers), open-label, randomized controlled phase II/III trial.”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Selected eligibility criteria

> “Histologically proven DLBCL from surgical resection or biopsy of an intracranial lesion.”
> “Age: 18 years or older.”
> “Eastern Cooperative Oncology Group performance status of 0–2, or 3 due to tumor-related neurological symptoms.”
> “No prior RT for PCNSL.”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Tirabrutinib treatment

> “Tirabrutinib is administered orally at a dose of 480 mg once daily under fasting conditions.”
> “The treatment will be continued until disease progression, unacceptable toxicity, or any other protocol-defined reason for discontinuation.”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="topic-3.1.4.5-2"></a>

###### Radiotherapy treatment

> “Patients in the RT arm will receive WBRT followed by a local boost to the residual parenchymal lesions after induction therapy.”
> “In total, 40 Gy in 20 fractions will be delivered over ~4 weeks, consisting of 30 Gy in 15 fractions for WBRT (2 Gy per fraction, once daily, 5 days/week), and a subsequent local boost of 10 Gy in 5 fractions (2 Gy per fraction).”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Overall Survival as the Phase III Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Overall survival definition and analysis role

> “In phase III, the primary endpoint is OS in all randomized patients analyzed on an intent-to-treat basis.”
> “OS is defined as the time from randomization to death from any cause and will be censored on the last day of contact for a surviving patient.”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="topic-3.1.4.6.1-2"></a>

###### Phase II continuation endpoint

> “In phase II, the primary endpoint is the proportion of patients in the tirabrutinib arm who continue tirabrutinib without disease progression at 4 weeks after treatment initiation.”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="topic-3.1.4.6.1-3"></a>

###### Quality-of-life measurement

> “QOL score will be measured using EORTC QLQ-C30 and EORTC QLQ-BN20.”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Sample size, margin, and power

> “To account for potential loss to follow-up, the planned sample size for phase III is set at 94 patients, including those enrolled in phase II.”
> “a non-inferiority margin of 5 months (corresponding to a hazard ratio of 1.50)”
> “a power of 70% with a one-sided alpha level of 10%”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Analysis populations and phase II stopping rule

> “All treated patients, including those who discontinued tirabrutinib for reasons other than disease progression, are included in the analysis population.”
> “In phase III, the primary endpoint is OS in all randomized patients analyzed on an intent-to-treat basis.”
> “Advancement to phase III will proceed only if at least 50% (≥5 of these 10 patients) remain on tirabrutinib without disease progression at 4 weeks.”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="topic-3.1.4.7.2-2"></a>

###### Interim analysis

> “We plan to conduct one interim analysis, considering multiplicity, using the Lan-DeMets method with the O’Brien and Fleming-type alpha spending function”

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The protocol describes an open-label comparison in induction-refractory PCNSL, not a completed efficacy analysis. The phase III plan includes 94 participants, a non-inferiority hazard-ratio margin of 1.50, 70% power, and a one-sided alpha of 10%. These design choices require consideration when interpreting any future non-inferiority finding. Overall survival and functional or cognitive outcomes must be distinguished from the phase II four-week treatment-continuation criterion.

Source: [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)

<a id="heading-3.1.5"></a>

#### 3.1.5 Japanese post-marketing surveillance

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Real-world safety and effectiveness objective

> “This post-marketing surveillance evaluated the safety and effectiveness of tirabrutinib in patients with relapsed/refractory primary central nervous system lymphoma (r/r PCNSL) in a real-world setting in Japan.”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Registration period and observation duration

> “All patients with r/r PCNSL who started treatment with tirabrutinib between May 20 and 31 October 2020, were registered.”
> “Adverse drug reactions (ADRs) and effectiveness were assessed over 52-weeks from the start of tirabrutinib treatment.”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Observational surveillance design

> “This was a prospective, non-interventional, observational PMS which evaluated the safety and effectiveness of tirabrutinib over the 52-week period from the first dose in patients with r/r PCNSL in Japan.”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Registered population

> “All patients with r/r PCNSL who started treatment with tirabrutinib between May 20 and 31 October 2020, were registered.”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Routine-care treatment

> “No invasive or interventional procedures were performed on the patients for the purpose of this surveillance; only clinical information was collected from routine medical practice”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Adverse Drug Reactions as the Safety Outcome

<a id="topic-3.1.5.6.1-1"></a>

###### Safety and effectiveness observation

> “Adverse drug reactions (ADRs) and effectiveness were assessed over 52-weeks from the start of tirabrutinib treatment.”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Safety and effectiveness population sizes

> “Of the 189 patients assessed for safety, 52.4% were male, the median age was 70.0 years (range 30-88), and 49.2% of patients had a Karnofsky performance status score of ≤60.”
> “Among the 121 patients assessed for effectiveness, the overall response rate evaluated by the treating physicians was 61.2%, and the 365-day survival rate was 69.8%.”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Analysis-set construction

> “After combining 10 transferred patients with the original cases and excluding 43 whose consent for disclosure was not obtained from patients or facilities, 189 patients were included in the safety analysis set.”
> “These 68 patients were excluded from the effectiveness analysis set, hence a total of 121 patients were included in the effectiveness analysis set.”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="topic-3.1.5.7.2-2"></a>

###### Descriptive analysis and confidence intervals

> “Descriptive statistics were used to summarize all patients’ baseline characteristics, treatment status, and safety and effectiveness parameters including ADRs and tumor response.”
> “The 95% confidence intervals were determined by the Clopper-Pearson exact method.”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Registration and case report forms

> “A total of 244 patients who started treatment with tirabrutinib between May 20 and 31 October 2020, were registered in this surveillance; case report forms were collected from 242 of these patients”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Safety population baseline characteristics

> “Of the 189 patients assessed for safety, 52.4% were male, the median age was 70.0 years (range 30-88), and 49.2% of patients had a Karnofsky performance status score of ≤60.”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Physician-assessed response

> “the overall response rate evaluated by the treating physicians was 61.2%”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Adverse drug reactions

> “ADRs of any grade and grade ≥3 were observed in 55.6% and 24.3%”

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

This prospective observational surveillance had no randomized comparator. Safety was assessed in 189 participants and effectiveness in 121, so the response rate must not be interpreted using the safety-population denominator. Response was assessed by treating physicians. The 52-week observation period limits assessment of later outcomes.

Source: [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)

<a id="heading-3.1.6"></a>

#### 3.1.6 ROSETTA

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Prolonged-effectiveness subgroup objective

> “We analyzed patient characteristics influencing prolonged effectiveness of tirabrutinib.”

Source: [Yamasaki et al. (2025b)](https://academic.oup.com/neuro-oncology/article/27/Supplement_5/v128/8318850)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Treatment initiation period

> “November 1, 2020 to April 30, 2023”

Source: [Nagane et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper198558.html)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Retrospective multicenter design

> “multi-center retrospective cohort study”

Source: [Nagane et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper198558.html)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

Additional sources: [Nagane et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper198558.html)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Tirabrutinib treatment

> “TIR monotherapy”

Source: [Nagane et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper198558.html)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Overall Response Rate as an Effectiveness Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Endpoint rationale

No evidence found.

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Original interim population

> “One hundred sixty-one patients with r/r PCNSL from 51 centers in Japan were enrolled in this study.”

Source: [Nagane et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper198558.html)

<a id="topic-3.1.6.7.1-2"></a>

###### Corrected real-world progression-free survival population

> “N = 158”

Source: [Ono Pharmaceutical corrected ROSETTA real-world progression-free survival figure](https://www.ono-ma.jp/sites/default/files/tirabrutinib/1_T.png)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

Additional sources: [Nagane et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper198558.html)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Baseline characteristics

| Measure | Quoted value |
| --- | --- |
| Median age, years | “71” |
| Median KPS | “70” |

Source: [Nagane et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper198558.html)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Original interim response and progression-free survival

> “The ORR and complete response/unconfirmed complete response (CR/CRu) rates were 77.4% and 55.5%, respectively.”
> “The median PFS was 11.8 (95% CI, 8.4–18.2) months”

Source: [Nagane et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper198558.html)

<a id="topic-3.1.6.8.3-2"></a>

###### Corrected real-world progression-free survival figure

> “rwPFS in all patients”
> “Median rwPFS [95% CI]”
> “11.6 mo [8.5–17.3]”

Source: [Ono Pharmaceutical corrected ROSETTA real-world progression-free survival figure](https://www.ono-ma.jp/sites/default/files/tirabrutinib/1_T.png)

Additional sources: [Ono Pharmaceutical corrected ROSETTA data notice](https://www.ono-ma.jp/tirabrutinib2)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

Additional sources: [Nagane et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper198558.html)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

ROSETTA is a retrospective multicenter study without a randomized comparator. The original interim abstract describes 161 participants, whereas the corrected real-world progression-free survival figure identifies 158. The original median progression-free survival estimate of 11.8 months and the corrected estimate of 11.6 months are retained separately; their populations and analysis versions should not be treated as interchangeable.

Source: [Nagane et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper198558.html); [Ono Pharmaceutical corrected ROSETTA real-world progression-free survival figure](https://www.ono-ma.jp/sites/default/files/tirabrutinib/1_T.png)

<a id="heading-3.1.7"></a>

#### 3.1.7 Single-center retrospective cohort

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

Additional sources: [Yamasaki et al. (2025a)](https://academic.oup.com/neuro-oncology/article/27/Supplement_3/iii157/8272092)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Treatment period and study population

> “Thirty-five patients with recurrent or refractory PCNSL treated with tirabrutinib at our institution between 2020 and 2025 were included.”

Source: [Yamasaki et al. (2025a)](https://academic.oup.com/neuro-oncology/article/27/Supplement_3/iii157/8272092)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Retrospective design

> “single center retrospective study”

Source: [Yamasaki et al. (2025a)](https://academic.oup.com/neuro-oncology/article/27/Supplement_3/iii157/8272092)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

Additional sources: [Yamasaki et al. (2025a)](https://academic.oup.com/neuro-oncology/article/27/Supplement_3/iii157/8272092)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

Additional sources: [Yamasaki et al. (2025a)](https://academic.oup.com/neuro-oncology/article/27/Supplement_3/iii157/8272092)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Time to Treatment Failure as an Effectiveness Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Endpoint rationale

No evidence found.

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Yamasaki et al. (2025a)](https://academic.oup.com/neuro-oncology/article/27/Supplement_3/iii157/8272092)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Median age by disease status

| Measure | Quoted value |
| --- | --- |
| Recurrent disease, years | “70” |
| Refractory disease, years | “74” |

Source: [Yamasaki et al. (2025a)](https://academic.oup.com/neuro-oncology/article/27/Supplement_3/iii157/8272092)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Reported outcomes by disease status

| Measure | Quoted value |
| --- | --- |
| Complete response, refractory disease: cases | “13” |
| Complete response, recurrent disease: cases | “11” |
| Time to treatment failure, refractory disease: months | “7.9” |
| Time to treatment failure, recurrent disease: months | “14.2” |
| Overall survival, refractory disease: months | “25” |
| Overall survival, recurrent disease: months | “32.4” |

Source: [Yamasaki et al. (2025a)](https://academic.oup.com/neuro-oncology/article/27/Supplement_3/iii157/8272092)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Severe pulmonary and hepatic adverse events

> “grade 3 interstitial pneumonia or liver failure”

Source: [Yamasaki et al. (2025a)](https://academic.oup.com/neuro-oncology/article/27/Supplement_3/iii157/8272092)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

The cohort included 35 participants treated at one institution between 2020 and 2025. Its retrospective design and separate recurrent and refractory groups limit causal interpretation of differences in treatment-failure and survival estimates. There was no randomized comparator in the reported design.

Source: [Yamasaki et al. (2025a)](https://academic.oup.com/neuro-oncology/article/27/Supplement_3/iii157/8272092)

<a id="heading-3.1.8"></a>

#### 3.1.8 Taiwan multicenter salvage-treatment cohort

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

Additional sources: [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Observation period

> “July 2021 and December 2023”

Source: [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Retrospective design

> “retrospective analysis”

Source: [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Access program

> “compassionate use program”

Source: [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

Additional sources: [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Overall Response Rate as an Effectiveness Endpoint

<a id="topic-3.1.8.6.1-1"></a>

###### Endpoint rationale

No evidence found.

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Analysis population sizes

| Measure | Quoted value |
| --- | --- |
| Safety population | “18” |
| Effectiveness population | “17” |

Source: [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

<a id="topic-3.1.8.7.2-1"></a>

###### Safety-only inclusion

> “One patient was only included in safety analysis”

Source: [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

###### Median age and range

> “Their median age was 63 years (26-88 years).”

Source: [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Overall response

> “The overall response was 64%”

Source: [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

###### Severe infections

> “Infections were observed in 6 patients (33%) and all were worse than grade 3”

Source: [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

This retrospective cohort included 18 participants in the safety population and 17 in the effectiveness population. One participant contributed only to the safety analysis. The response estimate and infection proportion therefore have different denominators, and neither establishes comparative benefit or harm against another treatment.

Source: [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)

<a id="heading-3.1.9"></a>

#### 3.1.9 REVEAL

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

No evidence found.

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

No evidence found.

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

No evidence found.

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

No evidence found.

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using Real-world Clinical Outcomes as the Study Outcomes

No evidence found.

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

Additional sources: [Hsiao et al. (2026b)](https://library.ehaweb.org/eha/2026/eha-2026/4208702/liang-tsai.hsiao.real-world.durable.clinical.benefits.of.tirabrutinib.and.its.html)

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

No evidence found.

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

No evidence found.

<a id="heading-3.1.10"></a>

#### 3.1.10 Treatment when standard therapy is difficult

<a id="heading-3.1.10.1"></a>

##### 3.1.10.1 Objective

Additional sources: [Yoshioka et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35896257/)

<a id="heading-3.1.10.2"></a>

##### 3.1.10.2 Location and Study Date

No evidence found.

<a id="heading-3.1.10.3"></a>

##### 3.1.10.3 Study Design

Additional sources: [Yoshioka et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35896257/)

<a id="heading-3.1.10.4"></a>

##### 3.1.10.4 Eligibility Criteria

<a id="topic-3.1.10.4-1"></a>

###### Reasons standard treatment was difficult

> “low KPS, renal dysfunction, and resistance to HD-MTX”

Source: [Yoshioka et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35896257/)

<a id="heading-3.1.10.5"></a>

##### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

###### Administration for swallowing difficulties

> “in suspension through a nasogastric tube”

Source: [Yoshioka et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35896257/)

<a id="heading-3.1.10.6"></a>

##### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

###### 3.1.10.6.1 Rationale for Using Clinical Response as an Observed Outcome

Not applicable.

<a id="heading-3.1.10.7"></a>

##### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

###### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Yoshioka et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35896257/)

<a id="heading-3.1.10.7.2"></a>

###### 3.1.10.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.10.8"></a>

##### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

###### 3.1.10.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.10.8.2"></a>

###### 3.1.10.8.2 Baseline Characteristics

<a id="topic-3.1.10.8.2-1"></a>

###### Baseline characteristics

| Measure | Quoted value |
| --- | --- |
| Median age, years | “76” |
| Median KPS | “40” |

Source: [Yoshioka et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35896257/)

<a id="heading-3.1.10.8.3"></a>

###### 3.1.10.8.3 Efficacy Results

<a id="topic-3.1.10.8.3-1"></a>

###### Clinical responses in the reported series

> “In the present study, five cases of refractory/relapsed PCNSL that are difficult to treat with standard treatment were successfully treated by tirabrutinib.”

Source: [Yoshioka et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35896257/)

<a id="topic-3.1.10.8.3-2"></a>

###### Reported response and survival

| Measure | Quoted value |
| --- | --- |
| Response rate | “100%” |
| Median survival | “8 months” |

Source: [Yoshioka et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35896257/)

<a id="heading-3.1.10.8.4"></a>

###### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.10.8.5"></a>

###### 3.1.10.8.5 Safety Results

<a id="topic-3.1.10.8.5-1"></a>

###### Adverse reactions

> “Three patients developed adverse reactions”

Source: [Yoshioka et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35896257/)

<a id="heading-3.1.10.9"></a>

##### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

###### Summary

This five-case series describes selected participants for whom standard treatment was difficult because of low KPS, renal dysfunction, or resistance to high-dose methotrexate. The reported 100% response rate is based on five participants and has no concurrent control group. It should not be treated as a population-level comparative efficacy estimate.

Source: [Yoshioka et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35896257/)

<a id="heading-3.1.11"></a>

#### 3.1.11 Long-term treatment and neurotoxicity case series

<a id="heading-3.1.11.1"></a>

##### 3.1.11.1 Objective

Additional sources: [Khairunnisa et al. (2024)](https://www.jstage.jst.go.jp/article/nmccrj/11/0/11_2024-0098/_html/-char/en)

<a id="heading-3.1.11.2"></a>

##### 3.1.11.2 Location and Study Date

No evidence found.

<a id="heading-3.1.11.3"></a>

##### 3.1.11.3 Study Design

Additional sources: [Khairunnisa et al. (2024)](https://www.jstage.jst.go.jp/article/nmccrj/11/0/11_2024-0098/_html/-char/en)

<a id="heading-3.1.11.4"></a>

##### 3.1.11.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.11.5"></a>

##### 3.1.11.5 Treatment

<a id="topic-3.1.11.5-1"></a>

###### Reported dosage

> “480 mg of tirabrutinib daily under fasting conditions”

Source: [Khairunnisa et al. (2024)](https://www.jstage.jst.go.jp/article/nmccrj/11/0/11_2024-0098/_html/-char/en)

<a id="heading-3.1.11.6"></a>

##### 3.1.11.6 Study Outcomes

<a id="heading-3.1.11.6.1"></a>

###### 3.1.11.6.1 Rationale for Using Clinical Response as an Observed Outcome

Not applicable.

<a id="heading-3.1.11.7"></a>

##### 3.1.11.7 Statistical Analysis Description

<a id="heading-3.1.11.7.1"></a>

###### 3.1.11.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Khairunnisa et al. (2024)](https://www.jstage.jst.go.jp/article/nmccrj/11/0/11_2024-0098/_html/-char/en)

<a id="heading-3.1.11.7.2"></a>

###### 3.1.11.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.11.8"></a>

##### 3.1.11.8 Results

<a id="heading-3.1.11.8.1"></a>

###### 3.1.11.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.11.8.2"></a>

###### 3.1.11.8.2 Baseline Characteristics

<a id="topic-3.1.11.8.2-1"></a>

###### Reported participants

> “76-year-old woman”
> “80-year-old man”

Source: [Khairunnisa et al. (2024)](https://www.jstage.jst.go.jp/article/nmccrj/11/0/11_2024-0098/_html/-char/en)

<a id="heading-3.1.11.8.3"></a>

###### 3.1.11.8.3 Efficacy Results

<a id="topic-3.1.11.8.3-1"></a>

###### Remission and treatment-duration observations

> “Complete remission was achieved.”
> “Complete remission was achieved, with no cognitive deterioration observed after 32 months of tirabrutinib administration.”
> “Complete remission was achieved. After 20 months of continuous tirabrutinib administration, his KPS improved to 90%, and his MMSE score to 29.”

Source: [Khairunnisa et al. (2024)](https://www.jstage.jst.go.jp/article/nmccrj/11/0/11_2024-0098/_html/-char/en)

<a id="heading-3.1.11.8.4"></a>

###### 3.1.11.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.11.8.5"></a>

###### 3.1.11.8.5 Safety Results

<a id="topic-3.1.11.8.5-1"></a>

###### Long-term neurological safety observations

> “In this report, we describe 2 cases of long-term tirabrutinib treatment without neurotoxicity or leukoencephalopathy.”

Source: [Khairunnisa et al. (2024)](https://www.jstage.jst.go.jp/article/nmccrj/11/0/11_2024-0098/_html/-char/en)

<a id="heading-3.1.11.9"></a>

##### 3.1.11.9 Study Limitations

<a id="topic-3.1.11.9-1"></a>

###### Summary

Two reported cases had long-term treatment without described neurotoxicity or leukoencephalopathy. This uncontrolled case series cannot establish the incidence of neurological toxicity or comparative neurological safety.

Source: [Khairunnisa et al. (2024)](https://www.jstage.jst.go.jp/article/nmccrj/11/0/11_2024-0098/_html/-char/en)

<a id="heading-3.1.12"></a>

#### 3.1.12 Tirabrutinib rechallenge case report

<a id="heading-3.1.12.1"></a>

##### 3.1.12.1 Objective

Additional sources: [Kawauchi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12696247/)

<a id="heading-3.1.12.2"></a>

##### 3.1.12.2 Location and Study Date

No evidence found.

<a id="heading-3.1.12.3"></a>

##### 3.1.12.3 Study Design

Additional sources: [Kawauchi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12696247/)

<a id="heading-3.1.12.4"></a>

##### 3.1.12.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.12.5"></a>

##### 3.1.12.5 Treatment

<a id="topic-3.1.12.5-1"></a>

###### Reported tirabrutinib dosage

> “tirabrutinib (480 mg/day)”

Source: [Kawauchi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12696247/)

<a id="heading-3.1.12.6"></a>

##### 3.1.12.6 Study Outcomes

<a id="heading-3.1.12.6.1"></a>

###### 3.1.12.6.1 Rationale for Using Clinical Response as an Observed Outcome

Not applicable.

<a id="heading-3.1.12.7"></a>

##### 3.1.12.7 Statistical Analysis Description

<a id="heading-3.1.12.7.1"></a>

###### 3.1.12.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Kawauchi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12696247/)

<a id="heading-3.1.12.7.2"></a>

###### 3.1.12.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.12.8"></a>

##### 3.1.12.8 Results

<a id="heading-3.1.12.8.1"></a>

###### 3.1.12.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.12.8.2"></a>

###### 3.1.12.8.2 Baseline Characteristics

<a id="topic-3.1.12.8.2-1"></a>

###### Presentation

> “A 75-year-old man presented with gait disturbance, dysarthria, and ataxia.”

Source: [Kawauchi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12696247/)

<a id="heading-3.1.12.8.3"></a>

###### 3.1.12.8.3 Efficacy Results

<a id="topic-3.1.12.8.3-1"></a>

###### Rechallenge response duration

> “A third recurrence led to a tirabrutinib rechallenge, and remission lasted five months.”

Source: [Kawauchi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12696247/)

<a id="heading-3.1.12.8.4"></a>

###### 3.1.12.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.12.8.5"></a>

###### 3.1.12.8.5 Safety Results

No evidence found.

<a id="heading-3.1.12.9"></a>

##### 3.1.12.9 Study Limitations

<a id="topic-3.1.12.9-1"></a>

###### Summary

A single participant experienced five months of remission after tirabrutinib rechallenge. This observation does not establish the probability of response to rechallenge, an optimal retreatment interval, or comparative benefit.

Source: [Kawauchi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12696247/)

<a id="heading-3.1.13"></a>

#### 3.1.13 Pseudoprogression during tirabrutinib treatment

<a id="heading-3.1.13.1"></a>

##### 3.1.13.1 Objective

Additional sources: [Okawara et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721748/)

<a id="heading-3.1.13.2"></a>

##### 3.1.13.2 Location and Study Date

No evidence found.

<a id="heading-3.1.13.3"></a>

##### 3.1.13.3 Study Design

Additional sources: [Okawara et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721748/)

<a id="heading-3.1.13.4"></a>

##### 3.1.13.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.13.5"></a>

##### 3.1.13.5 Treatment

<a id="topic-3.1.13.5-1"></a>

###### Continued treatment

> “TIR monotherapy”

Source: [Okawara et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721748/)

<a id="heading-3.1.13.6"></a>

##### 3.1.13.6 Study Outcomes

<a id="heading-3.1.13.6.1"></a>

###### 3.1.13.6.1 Rationale for Using Radiological Response as an Observed Outcome

Not applicable.

<a id="heading-3.1.13.7"></a>

##### 3.1.13.7 Statistical Analysis Description

<a id="heading-3.1.13.7.1"></a>

###### 3.1.13.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Okawara et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721748/)

<a id="heading-3.1.13.7.2"></a>

###### 3.1.13.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.13.8"></a>

##### 3.1.13.8 Results

<a id="heading-3.1.13.8.1"></a>

###### 3.1.13.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.13.8.2"></a>

###### 3.1.13.8.2 Baseline Characteristics

<a id="topic-3.1.13.8.2-1"></a>

###### Age and disease distribution

> “A 79-year-old woman had relapsed PCNSL with multiple tumor lesions in the lateral ventricles.”

Source: [Okawara et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721748/)

<a id="heading-3.1.13.8.3"></a>

###### 3.1.13.8.3 Efficacy Results

<a id="topic-3.1.13.8.3-1"></a>

###### Clinical course despite radiological enlargement

> “Despite the enlarged tumors, the patient remained asymptomatic, and re-remission was achieved by continuation of TIR monotherapy.”

Source: [Okawara et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721748/)

<a id="heading-3.1.13.8.4"></a>

###### 3.1.13.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.13.8.5"></a>

###### 3.1.13.8.5 Safety Results

No evidence found.

<a id="heading-3.1.13.9"></a>

##### 3.1.13.9 Study Limitations

<a id="topic-3.1.13.9-1"></a>

###### Summary

This single case describes radiological enlargement followed by re-remission during continued tirabrutinib monotherapy. It does not establish the frequency of pseudoprogression or justify assuming that enlargement during treatment is benign in other participants.

Source: [Okawara et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721748/)

<a id="heading-3.1.14"></a>

#### 3.1.14 Bridging treatment before autologous transplantation

<a id="heading-3.1.14.1"></a>

##### 3.1.14.1 Objective

<a id="topic-3.1.14.1-1"></a>

###### Bridging-treatment report

> “We herein report a case of relapsed primary DLBCL of the CNS complicated with primary biliary cholangitis, cirrhosis, and pancytopenia that was successfully treated with bridging therapy with tirabrutinib before autologous hematopoietic stem cell transplantation (ASCT).”

Source: [Nakagawa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9163585/)

<a id="heading-3.1.14.2"></a>

##### 3.1.14.2 Location and Study Date

<a id="topic-3.1.14.2-1"></a>

###### Institution

> “Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan”

Source: [Nakagawa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9163585/)

<a id="heading-3.1.14.3"></a>

##### 3.1.14.3 Study Design

Additional sources: [Nakagawa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9163585/)

<a id="heading-3.1.14.4"></a>

##### 3.1.14.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.14.5"></a>

##### 3.1.14.5 Treatment

<a id="topic-3.1.14.5-1"></a>

###### Treatment and dosage

> “She received tirabrutinib and intravitreal methotrexate for relapsed disease.”
> “Her starting dose of tirabrutinib was 320 mg once a day, and she continued the same dose.”

Source: [Nakagawa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9163585/)

<a id="heading-3.1.14.6"></a>

##### 3.1.14.6 Study Outcomes

<a id="heading-3.1.14.6.1"></a>

###### 3.1.14.6.1 Rationale for Using Clinical Response as an Observed Outcome

Not applicable.

<a id="heading-3.1.14.7"></a>

##### 3.1.14.7 Statistical Analysis Description

<a id="heading-3.1.14.7.1"></a>

###### 3.1.14.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Nakagawa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9163585/)

<a id="heading-3.1.14.7.2"></a>

###### 3.1.14.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.14.8"></a>

##### 3.1.14.8 Results

<a id="heading-3.1.14.8.1"></a>

###### 3.1.14.8.1 Participant Disposition

<a id="topic-3.1.14.8.1-1"></a>

###### Post-transplant engraftment

> “Neutrophil engraftment occurred on day 13.”

Source: [Nakagawa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9163585/)

<a id="heading-3.1.14.8.2"></a>

###### 3.1.14.8.2 Baseline Characteristics

<a id="topic-3.1.14.8.2-1"></a>

###### Age, presentation, and comorbidities

> “A 53-year-old woman was referred to our hospital with a chief complaint of dizziness.”
> “She had PBC, cirrhosis (Child-Pugh A), and pancytopenia due to hypersplenism as comorbidity.”

Source: [Nakagawa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9163585/)

<a id="heading-3.1.14.8.3"></a>

###### 3.1.14.8.3 Efficacy Results

<a id="topic-3.1.14.8.3-1"></a>

###### Response before and after transplantation

> “Her brain lesion was ameliorated after four weeks of tirabrutinib.”
> “No relapse of her lymphoma was noted during the follow-up period of 6 months after ASCT.”

Source: [Nakagawa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9163585/)

<a id="heading-3.1.14.8.4"></a>

###### 3.1.14.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.14.8.5"></a>

###### 3.1.14.8.5 Safety Results

<a id="topic-3.1.14.8.5-1"></a>

###### Reported post-transplant safety

> “Veno-occlusive disease/sinusoidal obstruction syndrome did not occur.”

Source: [Nakagawa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9163585/)

<a id="heading-3.1.14.9"></a>

##### 3.1.14.9 Study Limitations

<a id="topic-3.1.14.9-1"></a>

###### Summary

This report concerns one participant who received tirabrutinib together with intravitreal methotrexate and subsequently underwent autologous transplantation. The post-transplant absence of relapse cannot be attributed to tirabrutinib alone. A tolerated 320 mg daily dose in this case does not establish a dosing regimen for other participants with cirrhosis.

Source: [Nakagawa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9163585/)

<a id="heading-3.1.15"></a>

#### 3.1.15 Relapsed primary spinal-cord lymphoma case report

<a id="heading-3.1.15.1"></a>

##### 3.1.15.1 Objective

Additional sources: [Ishi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41243010/)

<a id="heading-3.1.15.2"></a>

##### 3.1.15.2 Location and Study Date

No evidence found.

<a id="heading-3.1.15.3"></a>

##### 3.1.15.3 Study Design

<a id="topic-3.1.15.3-1"></a>

###### Publication design

> “Case report.”

Source: [Ishi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41243010/)

<a id="heading-3.1.15.4"></a>

##### 3.1.15.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.15.5"></a>

##### 3.1.15.5 Treatment

Additional sources: [Ishi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41243010/)

<a id="heading-3.1.15.6"></a>

##### 3.1.15.6 Study Outcomes

<a id="heading-3.1.15.6.1"></a>

###### 3.1.15.6.1 Rationale for Using Clinical Response as an Observed Outcome

Not applicable.

<a id="heading-3.1.15.7"></a>

##### 3.1.15.7 Statistical Analysis Description

<a id="heading-3.1.15.7.1"></a>

###### 3.1.15.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Ishi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41243010/)

<a id="heading-3.1.15.7.2"></a>

###### 3.1.15.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.15.8"></a>

##### 3.1.15.8 Results

<a id="heading-3.1.15.8.1"></a>

###### 3.1.15.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.15.8.2"></a>

###### 3.1.15.8.2 Baseline Characteristics

<a id="topic-3.1.15.8.2-1"></a>

###### Presentation

> “A 58-year-old male presented with progressive numbness from the neck down and neck pain.”

Source: [Ishi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41243010/)

<a id="heading-3.1.15.8.3"></a>

###### 3.1.15.8.3 Efficacy Results

<a id="topic-3.1.15.8.3-1"></a>

###### Tumor remission and follow-up

> “Tumor remission was achieved with TIR, and the patient showed no relapse for 42 months after starting TIR.”

Source: [Ishi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41243010/)

<a id="heading-3.1.15.8.4"></a>

###### 3.1.15.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.15.8.5"></a>

###### 3.1.15.8.5 Safety Results

No evidence found.

<a id="heading-3.1.15.9"></a>

##### 3.1.15.9 Study Limitations

<a id="topic-3.1.15.9-1"></a>

###### Summary

This single case describes remission and 42 months without reported relapse after starting tirabrutinib for primary spinal-cord lymphoma. It does not establish response frequency or comparative benefit in broader PCNSL populations.

Source: [Ishi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41243010/)

<a id="heading-3.1.16"></a>

#### 3.1.16 Vitreoretinal lymphoma with spinal-cord involvement

<a id="heading-3.1.16.1"></a>

##### 3.1.16.1 Objective

Additional sources: [Iizuka-Honma et al. (2023)](https://www.jstage.jst.go.jp/article/internalmedicine/62/3/62_9591-22/_article/-char/en)

<a id="heading-3.1.16.2"></a>

##### 3.1.16.2 Location and Study Date

No evidence found.

<a id="heading-3.1.16.3"></a>

##### 3.1.16.3 Study Design

Additional sources: [Iizuka-Honma et al. (2023)](https://www.jstage.jst.go.jp/article/internalmedicine/62/3/62_9591-22/_article/-char/en)

<a id="heading-3.1.16.4"></a>

##### 3.1.16.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.16.5"></a>

##### 3.1.16.5 Treatment

Additional sources: [Iizuka-Honma et al. (2023)](https://www.jstage.jst.go.jp/article/internalmedicine/62/3/62_9591-22/_article/-char/en)

<a id="heading-3.1.16.6"></a>

##### 3.1.16.6 Study Outcomes

<a id="heading-3.1.16.6.1"></a>

###### 3.1.16.6.1 Rationale for Using Clinical Response as an Observed Outcome

Not applicable.

<a id="heading-3.1.16.7"></a>

##### 3.1.16.7 Statistical Analysis Description

<a id="heading-3.1.16.7.1"></a>

###### 3.1.16.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Iizuka-Honma et al. (2023)](https://www.jstage.jst.go.jp/article/internalmedicine/62/3/62_9591-22/_article/-char/en)

<a id="heading-3.1.16.7.2"></a>

###### 3.1.16.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.16.8"></a>

##### 3.1.16.8 Results

<a id="heading-3.1.16.8.1"></a>

###### 3.1.16.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.16.8.2"></a>

###### 3.1.16.8.2 Baseline Characteristics

<a id="topic-3.1.16.8.2-1"></a>

###### Disease history and prior therapies

> “a patient with refractory PVRL”
> “recurrence in the spinal cord”
> “high-dose methotrexate-based chemotherapy and whole-brain radiotherapy”

Source: [Iizuka-Honma et al. (2023)](https://www.jstage.jst.go.jp/article/internalmedicine/62/3/62_9591-22/_article/-char/en)

<a id="heading-3.1.16.8.3"></a>

###### 3.1.16.8.3 Efficacy Results

<a id="topic-3.1.16.8.3-1"></a>

###### Temporary treatment response

> “The patient surprisingly responded to tirabrutinib temporarily.”

Source: [Iizuka-Honma et al. (2023)](https://www.jstage.jst.go.jp/article/internalmedicine/62/3/62_9591-22/_article/-char/en)

<a id="heading-3.1.16.8.4"></a>

###### 3.1.16.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.16.8.5"></a>

###### 3.1.16.8.5 Safety Results

No evidence found.

<a id="heading-3.1.16.9"></a>

##### 3.1.16.9 Study Limitations

<a id="topic-3.1.16.9-1"></a>

###### Summary

The retained case describes a temporary response in a participant with refractory vitreoretinal lymphoma and spinal-cord recurrence after chemotherapy and whole-brain radiotherapy. It does not provide a generalizable estimate of response duration or comparative efficacy.

Source: [Iizuka-Honma et al. (2023)](https://www.jstage.jst.go.jp/article/internalmedicine/62/3/62_9591-22/_article/-char/en)

<a id="heading-3.1.17"></a>

#### 3.1.17 Lymphomatosis cerebri case report

<a id="heading-3.1.17.1"></a>

##### 3.1.17.1 Objective

Additional sources: [Ono et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13317521/)

<a id="heading-3.1.17.2"></a>

##### 3.1.17.2 Location and Study Date

No evidence found.

<a id="heading-3.1.17.3"></a>

##### 3.1.17.3 Study Design

Additional sources: [Ono et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13317521/)

<a id="heading-3.1.17.4"></a>

##### 3.1.17.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.17.5"></a>

##### 3.1.17.5 Treatment

Additional sources: [Ono et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13317521/)

<a id="heading-3.1.17.6"></a>

##### 3.1.17.6 Study Outcomes

<a id="heading-3.1.17.6.1"></a>

###### 3.1.17.6.1 Rationale for Using Radiological Response as an Observed Outcome

Not applicable.

<a id="heading-3.1.17.7"></a>

##### 3.1.17.7 Statistical Analysis Description

<a id="heading-3.1.17.7.1"></a>

###### 3.1.17.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Ono et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13317521/)

<a id="heading-3.1.17.7.2"></a>

###### 3.1.17.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.17.8"></a>

##### 3.1.17.8 Results

<a id="heading-3.1.17.8.1"></a>

###### 3.1.17.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.17.8.2"></a>

###### 3.1.17.8.2 Baseline Characteristics

<a id="topic-3.1.17.8.2-1"></a>

###### Presentation

> “A 71-year-old woman presented with a 1-month history of nausea.”

Source: [Ono et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13317521/)

<a id="heading-3.1.17.8.3"></a>

###### 3.1.17.8.3 Efficacy Results

<a id="topic-3.1.17.8.3-1"></a>

###### Radiological outcome

> “Tirabrutinib was initiated, resulting in complete radiological resolution for 5 months.”

Source: [Ono et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13317521/)

<a id="heading-3.1.17.8.4"></a>

###### 3.1.17.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.17.8.5"></a>

###### 3.1.17.8.5 Safety Results

No evidence found.

<a id="heading-3.1.17.9"></a>

##### 3.1.17.9 Study Limitations

<a id="topic-3.1.17.9-1"></a>

###### Summary

This single case describes five months of complete radiological resolution after starting tirabrutinib. The observation does not establish response frequency, long-term disease control, or comparative benefit in lymphomatosis cerebri.

Source: [Ono et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13317521/)

<a id="heading-3.1.18"></a>

#### 3.1.18 Cutaneous adverse-event case series

<a id="heading-3.1.18.1"></a>

##### 3.1.18.1 Objective

Additional sources: [Matsunuma et al. (2026)](https://www.jstage.jst.go.jp/article/yakushi/146/2/146_25-00085/_article/-char/en)

<a id="heading-3.1.18.2"></a>

##### 3.1.18.2 Location and Study Date

<a id="topic-3.1.18.2-1"></a>

###### Treatment period

> “March 1, 2020, and February 29, 2024”

Source: [Matsunuma et al. (2026)](https://www.jstage.jst.go.jp/article/yakushi/146/2/146_25-00085/_article/-char/en)

<a id="heading-3.1.18.3"></a>

##### 3.1.18.3 Study Design

<a id="topic-3.1.18.3-1"></a>

###### Case-series design

> “single-center case series”

Source: [Matsunuma et al. (2026)](https://www.jstage.jst.go.jp/article/yakushi/146/2/146_25-00085/_article/-char/en)

<a id="heading-3.1.18.4"></a>

##### 3.1.18.4 Eligibility Criteria

Additional sources: [Matsunuma et al. (2026)](https://www.jstage.jst.go.jp/article/yakushi/146/2/146_25-00085/_article/-char/en)

<a id="heading-3.1.18.5"></a>

##### 3.1.18.5 Treatment

Additional sources: [Matsunuma et al. (2026)](https://www.jstage.jst.go.jp/article/yakushi/146/2/146_25-00085/_article/-char/en)

<a id="heading-3.1.18.6"></a>

##### 3.1.18.6 Study Outcomes

<a id="heading-3.1.18.6.1"></a>

###### 3.1.18.6.1 Rationale for Using Cutaneous Adverse Events as the Safety Outcome

Not applicable.

<a id="heading-3.1.18.7"></a>

##### 3.1.18.7 Statistical Analysis Description

<a id="heading-3.1.18.7.1"></a>

###### 3.1.18.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.18.7.1-1"></a>

###### Number of participants

> “Seven patients (mean age: 71.1 years, range, 52–88 years) were included herein.”

Source: [Matsunuma et al. (2026)](https://www.jstage.jst.go.jp/article/yakushi/146/2/146_25-00085/_article/-char/en)

<a id="heading-3.1.18.7.2"></a>

###### 3.1.18.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.18.8"></a>

##### 3.1.18.8 Results

<a id="heading-3.1.18.8.1"></a>

###### 3.1.18.8.1 Participant Disposition

<a id="topic-3.1.18.8.1-1"></a>

###### Treatment discontinuation

> “One patient discontinued tirabrutinib treatment because of severe cutaneous adverse events.”

Source: [Matsunuma et al. (2026)](https://www.jstage.jst.go.jp/article/yakushi/146/2/146_25-00085/_article/-char/en)

<a id="heading-3.1.18.8.2"></a>

###### 3.1.18.8.2 Baseline Characteristics

<a id="topic-3.1.18.8.2-1"></a>

###### Age

| Measure | Quoted value |
| --- | --- |
| Mean age, years | “71.1” |
| Age range, years | “52–88” |

Source: [Matsunuma et al. (2026)](https://www.jstage.jst.go.jp/article/yakushi/146/2/146_25-00085/_article/-char/en)

<a id="heading-3.1.18.8.3"></a>

###### 3.1.18.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.18.8.4"></a>

###### 3.1.18.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.18.8.5"></a>

###### 3.1.18.8.5 Safety Results

<a id="topic-3.1.18.8.5-1"></a>

###### Skin disorders

> “Skin disorders were observed in 5 patients (71.4%)”

Source: [Matsunuma et al. (2026)](https://www.jstage.jst.go.jp/article/yakushi/146/2/146_25-00085/_article/-char/en)

<a id="heading-3.1.18.9"></a>

##### 3.1.18.9 Study Limitations

<a id="topic-3.1.18.9-1"></a>

###### Summary

This single-center case series included seven participants, with skin disorders reported in five and treatment discontinuation because of severe cutaneous adverse events in one. The sample size and lack of a comparator limit estimation of population-level risk and comparative tolerability.

Source: [Matsunuma et al. (2026)](https://www.jstage.jst.go.jp/article/yakushi/146/2/146_25-00085/_article/-char/en)

<a id="heading-3.1.19"></a>

#### 3.1.19 Severe central nervous system fungal infection case report

<a id="heading-3.1.19.1"></a>

##### 3.1.19.1 Objective

<a id="topic-3.1.19.1-1"></a>

###### Reported infection

> “We report a case of severe Aspergillus encephalitis following tirabrutinib administration.”

Source: [Akimoto et al. (2026)](https://www.jstage.jst.go.jp/article/nmccrj/13/0/13_2026-0112/_html/-char/en)

<a id="heading-3.1.19.2"></a>

##### 3.1.19.2 Location and Study Date

No evidence found.

<a id="heading-3.1.19.3"></a>

##### 3.1.19.3 Study Design

Additional sources: [Akimoto et al. (2026)](https://www.jstage.jst.go.jp/article/nmccrj/13/0/13_2026-0112/_html/-char/en)

<a id="heading-3.1.19.4"></a>

##### 3.1.19.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.19.5"></a>

##### 3.1.19.5 Treatment

Additional sources: [Akimoto et al. (2026)](https://www.jstage.jst.go.jp/article/nmccrj/13/0/13_2026-0112/_html/-char/en)

<a id="heading-3.1.19.6"></a>

##### 3.1.19.6 Study Outcomes

<a id="heading-3.1.19.6.1"></a>

###### 3.1.19.6.1 Rationale for Using Fungal Infection as an Observed Safety Outcome

Not applicable.

<a id="heading-3.1.19.7"></a>

##### 3.1.19.7 Statistical Analysis Description

<a id="heading-3.1.19.7.1"></a>

###### 3.1.19.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Akimoto et al. (2026)](https://www.jstage.jst.go.jp/article/nmccrj/13/0/13_2026-0112/_html/-char/en)

<a id="heading-3.1.19.7.2"></a>

###### 3.1.19.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.19.8"></a>

##### 3.1.19.8 Results

<a id="heading-3.1.19.8.1"></a>

###### 3.1.19.8.1 Participant Disposition

<a id="topic-3.1.19.8.1-1"></a>

###### Fatal outcome

> “Subsequently, a fatal subcortical hemorrhage occurred.”

Source: [Akimoto et al. (2026)](https://www.jstage.jst.go.jp/article/nmccrj/13/0/13_2026-0112/_html/-char/en)

<a id="heading-3.1.19.8.2"></a>

###### 3.1.19.8.2 Baseline Characteristics

<a id="topic-3.1.19.8.2-1"></a>

###### Age and sex

> “A man in his 50s”

Source: [Akimoto et al. (2026)](https://www.jstage.jst.go.jp/article/nmccrj/13/0/13_2026-0112/_html/-char/en)

<a id="heading-3.1.19.8.3"></a>

###### 3.1.19.8.3 Efficacy Results

<a id="topic-3.1.19.8.3-1"></a>

###### Initial tumor response

> “The tumor shrank dramatically, and improvement in neurological symptoms was observed.”

Source: [Akimoto et al. (2026)](https://www.jstage.jst.go.jp/article/nmccrj/13/0/13_2026-0112/_html/-char/en)

<a id="heading-3.1.19.8.4"></a>

###### 3.1.19.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.19.8.5"></a>

###### 3.1.19.8.5 Safety Results

<a id="topic-3.1.19.8.5-1"></a>

###### Treatment interruption and hepatic toxicity

> “liver dysfunction”
> “tirabrutinib was discontinued.”

Source: [Akimoto et al. (2026)](https://www.jstage.jst.go.jp/article/nmccrj/13/0/13_2026-0112/_html/-char/en)

<a id="heading-3.1.19.9"></a>

##### 3.1.19.9 Study Limitations

<a id="topic-3.1.19.9-1"></a>

###### Summary

The report describes one participant with Aspergillus encephalitis after tirabrutinib exposure and a subsequent fatal subcortical hemorrhage. A case report can identify a possible safety signal but cannot determine incidence or establish that tirabrutinib alone caused the infection or hemorrhage.

Source: [Akimoto et al. (2026)](https://www.jstage.jst.go.jp/article/nmccrj/13/0/13_2026-0112/_html/-char/en)

<a id="heading-3.1.20"></a>

#### 3.1.20 Paranasal sinus aspergillosis case report

<a id="heading-3.1.20.1"></a>

##### 3.1.20.1 Objective

No evidence found.

<a id="heading-3.1.20.2"></a>

##### 3.1.20.2 Location and Study Date

No evidence found.

<a id="heading-3.1.20.3"></a>

##### 3.1.20.3 Study Design

Additional sources: [Kitamura and Kuyama (2022)](https://pubmed.ncbi.nlm.nih.gov/36121607/)

<a id="heading-3.1.20.4"></a>

##### 3.1.20.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.20.5"></a>

##### 3.1.20.5 Treatment

No evidence found.

<a id="heading-3.1.20.6"></a>

##### 3.1.20.6 Study Outcomes

<a id="heading-3.1.20.6.1"></a>

###### 3.1.20.6.1 Rationale for Using Fungal Infection as an Observed Safety Outcome

Not applicable.

<a id="heading-3.1.20.7"></a>

##### 3.1.20.7 Statistical Analysis Description

<a id="heading-3.1.20.7.1"></a>

###### 3.1.20.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Kitamura and Kuyama (2022)](https://pubmed.ncbi.nlm.nih.gov/36121607/)

<a id="heading-3.1.20.7.2"></a>

###### 3.1.20.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.20.8"></a>

##### 3.1.20.8 Results

<a id="heading-3.1.20.8.1"></a>

###### 3.1.20.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.20.8.2"></a>

###### 3.1.20.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.20.8.3"></a>

###### 3.1.20.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.20.8.4"></a>

###### 3.1.20.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.20.8.5"></a>

###### 3.1.20.8.5 Safety Results

No evidence found.

<a id="heading-3.1.20.9"></a>

##### 3.1.20.9 Study Limitations

No evidence found.

<a id="heading-3.1.21"></a>

#### 3.1.21 Suspension administration pharmacokinetic case report

<a id="heading-3.1.21.1"></a>

##### 3.1.21.1 Objective

Additional sources: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

<a id="heading-3.1.21.2"></a>

##### 3.1.21.2 Location and Study Date

<a id="topic-3.1.21.2-1"></a>

###### Location and initial presentation date

> “Tokyo”
> “February 2023”

Source: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

<a id="heading-3.1.21.3"></a>

##### 3.1.21.3 Study Design

<a id="topic-3.1.21.3-1"></a>

###### Publication design

> “Case report”

Source: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

<a id="heading-3.1.21.4"></a>

##### 3.1.21.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.21.5"></a>

##### 3.1.21.5 Treatment

<a id="topic-3.1.21.5-1"></a>

###### Reported daily dose

> “480 mg”

Source: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

<a id="heading-3.1.21.6"></a>

##### 3.1.21.6 Study Outcomes

<a id="heading-3.1.21.6.1"></a>

###### 3.1.21.6.1 Rationale for Using Plasma Tirabrutinib Concentration as an Exploratory Outcome

<a id="topic-3.1.21.6.1-1"></a>

###### Clinical bioequivalence validation

No evidence found.

<a id="heading-3.1.21.7"></a>

##### 3.1.21.7 Statistical Analysis Description

<a id="heading-3.1.21.7.1"></a>

###### 3.1.21.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

<a id="heading-3.1.21.7.2"></a>

###### 3.1.21.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.21.8"></a>

##### 3.1.21.8 Results

<a id="heading-3.1.21.8.1"></a>

###### 3.1.21.8.1 Participant Disposition

<a id="topic-3.1.21.8.1-1"></a>

###### Discharge after treatment initiation

> “day 23”

Source: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

<a id="heading-3.1.21.8.2"></a>

###### 3.1.21.8.2 Baseline Characteristics

<a id="topic-3.1.21.8.2-1"></a>

###### Age and sex

> “68-year-old man”

Source: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

<a id="heading-3.1.21.8.3"></a>

###### 3.1.21.8.3 Efficacy Results

<a id="topic-3.1.21.8.3-1"></a>

###### Concentrations by administration route

> “Plasma tirabrutinib concentrations were comparable following administration via nasogastric tube, oral suspension and oral tablets.”

Source: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

<a id="topic-3.1.21.8.3-2"></a>

###### Disease response

> “complete remission”

Source: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

<a id="heading-3.1.21.8.4"></a>

###### 3.1.21.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.21.8.5"></a>

###### 3.1.21.8.5 Safety Results

<a id="topic-3.1.21.8.5-1"></a>

###### Suspension-period safety

> “No adverse events were observed during the suspension administration period.”

Source: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

<a id="heading-3.1.21.9"></a>

##### 3.1.21.9 Study Limitations

<a id="topic-3.1.21.9-1"></a>

###### Summary

Comparable measured concentrations in a single case do not establish bioequivalence, a limitation explicitly acknowledged by the authors. No adverse events were observed during suspension administration; this observation does not estimate the frequency of uncommon harms.

Source: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

<a id="topic-3.1.21.9-2"></a>

###### Bioequivalence limitation

> “bioequivalence cannot be definitively confirmed.”

Source: [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)

## Related pages
- [Tirabrutinib: Primary central nervous system lymphoma](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Terms and abbreviations](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/terms-and-abbreviations.md)
- [Tirabrutinib: Primary central nervous system lymphoma](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/executive-summary.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Product information and disease description](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/product-information-and-disease-description.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Economic information and modeling report](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/economics) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/economics.md)
- [Tirabrutinib in Primary central nervous system lymphoma: References](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/references) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/references.md)
- [Tirabrutinib in Primary central nervous system lymphoma: prevalence by geography](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/prevalence) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/prevalence.md)
- [Tirabrutinib in Primary central nervous system lymphoma: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/cost-effectiveness-analyses.md)
